首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

International Journal Of Clinical Pharmacy

International Journal Of Clinical Pharmacy杂志,由Springer International Publishing出版,于1979年创刊,6 issues per year,出版语言English,ISSN:2210-7703,E-ISSN:2210-7711。

投稿咨询
International Journal Of Clinical Pharmacy
International Journal Of Clinical Pharmacy
International Journal Of Clinical Pharmacy
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
3区
影响因子
3.2
CiteScore
5
期刊收录
SCI、SCIE

International Journal Of Clinical Pharmacy(中文译名:《国际临床药学杂志》),ISSN:2210-7703,EISSN:2210-7711,是Springer International Publishing出版的国际性学术期刊,创刊于1979年,以6 issues per year形式稳定发行,2026年总发文量约188篇。该刊采用非OA开放访问,学科归属为PHARMACOLOGY & PHARMACY。该刊是医学、药学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3.2,2025年期刊CiteScore为5,2025年期刊自引率约18.8%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。International Journal Of Clinical Pharmacy长期聚焦医学、药学及相关产业的技术应用前沿,平均审稿周期偏慢,4-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,SpainFrance、Netherlands、USA、Australia、Turkey、England等为核心发文国家与地区;MARMARA UNIVERSITYASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP)、UTRECHT UNIVERSITY、ROBERT GORDON UNIVERSITY、UNIVERSITY OF BASEL、UNIVERSIDADE DE LISBOA、RADBOUD UNIVERSITY NIJMEGEN等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
PHARMACOLOGY & PHARMACY 药学
3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 156 / 356

56.3

学科:PHARMACOLOGY & PHARMACY SCIE Q2 135 / 356

62.22

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 173 / 354

51.3

学科:PHARMACOLOGY & PHARMACY SCIE Q3 207 / 354

41.67


中国学者近期发文

1
Drug-induced fever: a pharmacovigilance analysis based on the FDA adverse event reporting syste

Author:Li, Xiaozhi; Zhang, Weichun; Wen, Xiaofen; Lin, Danxia; Luo, Xiajiong

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02113-3

2
A novel predictive model for evaluating thrombus regression in postpartum venous thromboembolism patient

Author:Yu, Meixiang; Jia, Congcong; Zhou, Zhenyu; Chen, Qingshan; Di, Xuemei; Zhang, Ning; Zhang, Xiaoqing; Xu, Zhendong; Zhang, Hai

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02125-z

3
Cost-effectiveness of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China and the United States healthcare system

Author:Yang, Junhao; Ding, Haixia

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02133-z

4
Development of a real-world, therapeutic drug monitoring-informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infection

Author:Wang, Fusang; Zhang, Mei; Ye, Suiwen; Yan, Jianan; Li, Xuechun; Zhang, Jinyuan; Yu, Xiaoxia; Wang, Ying; Yu, Ze; Gao, Fei; Wu, Junyan

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02124-0

5
Development and validation of a LASSO-logistic regression model for predicting subtherapeutic infliximab trough concentrations in patients with Crohn's diseas

Author:Song, Jialin; Li, Xiaoyan; Wu, Wenjiao; Peng, Xiang; Xie, Jingwen; He, Xuelian; Wang, Yiting

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02106-2

6
Oral low-dose methotrexate improves infliximab pharmacokinetics, immunogenicity, and endoscopic outcomes in Crohn's disease: a propensity score-adjusted real-world stud

Author:Huang, Shangzhan; Li, Dongyan; Qin, Tingting; Tang, Feng; Ma, Runzhao; Shen, Yinxian; Liu, Haoying; Gong, Jin; Huang, Qionghui; Ke, Meng; Wang, Li; Dai, Anqi; Li, Juan; Liao, Jiazhi; Xiao, Fang

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02098-z

7
Burden of mental disorders in working-age populations (15-64 years) from 1990 to 2021 with projections to 2045: a global analysis of India, China and the United State

Author:Jiang, Ruiqi; Wang, Li; Tian, Yue; Zhao, Zhigang; Kuo, Alex; Cao, Mingnan

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02093-4

8
Patient preferences for community pharmacy service models in diabetes care: a discrete choice experimen

Author:Sun, Yu; Jia, Zizhen; Lan, Linyan; Xie, Xiangxiang; Xie, Han; Ji, Cheng

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-025-02080-1

9
Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedure

Author:Liu, Chenning; Lyu, Liyang; Zhang, Yufan; Tian, Yingyi; Yuan, Jing; Li, Chihua; Hu, Yuanjia

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02119-x

10
Pharmaceutical competency among physicians: a multidimensional assessment incorporating self-perceived and objective measure

Author:Liu, Chao; Guo, Hanyang; Li, Bingyi; Liu, Pengcheng; Yao, Wenbing

Journal: INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11096-026-02110-6


在线咨询

International Journal Of Clinical Pharmacy

国际简称:INT J CLIN PHARM-NET参考译名:国际临床药学杂志

年发文量:188 CiteScore:5 是否预警:否 Gold OA文章占比:46.11% 研究类文章占比:81.38%

杂志社联系方式:VAN GODEWIJCKSTRAAT 30, DORDRECHT, NETHERLANDS, 3311 GZ

International Journal Of Clinical Pharmacy